DENVER, February 17, 2022 /PRNewswire/ — Dialysis patients who received an adenovirus vector-based COVID-19 vaccine (Johnson & Johnson) had similar rates of breakthrough infection, hospitalization and mortality as dialysis patients who received a mRNA-based vaccine (Pfizer/BioNTech), according to a DaVita Clinical Research (DCR) study published online ahead of print by the Journal of the American Society of Nephrology.
“Vaccination remains the most effective way to prevent serious illness from COVID-19 for dialysis patients,” said Dr. steven brunelli, MCSE, Vice President of DCR. “Our observations provide assurance that adenovirus vector-based COVID-19 vaccination, such as that produced by Johnson & Johnson, is an effective clinical strategy to help protect these patients from COVID-19 and from hospitalization or associated mortality.
More than 500,000 people in the United States who have been diagnosed with end-stage renal disease (ESKD) are receiving life-saving dialysis care. Due to underlying health conditions that compromise their immune systems, these patients are at increased risk for COVID-19. While mRNA vaccines have been shown to be effective in dialysis patients, researchers have sought to understand the effectiveness of adenovirus vector-based vaccines, as patients may receive the Johnson & Johnson vaccine due to its availability or its personal choice.
To assess the effectiveness of the Johnson & Johnson vaccine in dialysis patients, the researchers matched patients who had received this vaccine with those who had received Pfizer/BioNTech. A total of 2,572 matched pairs were evaluated from February 27, 2021 at September 28, 2021. The study found no difference in COVID-19 infection rates among patients treated with the Johnson & Johnson vaccine compared to the Pfizer/BioNTech vaccine during the first six months after vaccination.
The study further demonstrates that both vaccines were equally effective in helping to reduce the risk of hospitalization and death in the event of a breakthrough infection.
Since the start of the COVID-19 pandemic, DCR has conducted several studies to better understand how the novel coronavirus behaves in medically vulnerable patients with ESKD. Related research efforts also include the first large study demonstrating clinical efficacy of COVID-19 mRNA vaccines in ESKD patients.
To view the study in full, visit online ahead of print by the Journal of the American Society of Nephrology. To learn more about DaVita Clinical Research, visit DaVitaClinicalResearch.com.
About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and execution of clinical trials using its network of renal research sites. To learn more about DCR, visit DaVitaClinicalResearch.com.
About DaVita Inc.
DaVita (NYSE: DVA) is a comprehensive kidney care provider focused on transforming care to improve the quality of life for patients around the world. The company is one of the largest providers of kidney care services in the United States and has been a leader in clinical quality and innovation for more than 20 years. DaVita strives to help increase equitable access to care for patients at every step and stage of their kidney health journey, from slowing the progression of kidney disease to streamlining the transplant process, from acute hospital care to home dialysis. From December 31, 2021, DaVita has served 203,000 patients at 2,815 ambulatory dialysis centers in the United States. The company operated 339 additional outpatient dialysis centers in ten countries around the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care community to adopt an equitable, high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
SOURCE DaVita Clinical Research